TerminatedPhase 1NCT02707666

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Chicago
Principal Investigator
Hedy Kindler, MD
University of Chicago
Intervention
Pembrolizumab(drug)
Enrollment
7 target
Eligibility
18 years · All sexes
Timeline
20162023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02707666 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma

← Back to all trials